article thumbnail

Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19)

Xconomy

Given the number of late-stage and mid-stage studies expected to report data in 2020—assuming they stay on track amid the COVID-19 pandemic—this could be a pivotal year for the field, said Isabelle de Cremoux, CEO and managing partner of Seventure Partners.

Class 138
article thumbnail

National Xconomy Awards Now Accepting Nominations for the Best in Biotech

Xconomy

The nomination period for the 2020 National Xconomy Awards is now open. Building on the popularity and strength of the 2017-2019 Boston Xconomy Awards and the 2019 San Diego Xconomy Awards, the 2020 National Xconomy Awards winners will be announced at a Monday, June 8 gala at the Hard Rock Hotel San Diego during.

San Diego 101
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

After Ending Cancer Drug Program, Halozyme Predicts Profits in 2020

Xconomy

The San Diego-based company’s technology, called Enhanze, allows some drugs traditionally given intravenously over hours to be delivered instead by subcutaneous injection in minutes.

article thumbnail

Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More

Xconomy

At the start of 2020 thousands of biotechies anticipated spending the second week of June in San Diego, hobnobbing at the annual conference hosted by the Biotechnology Innovation Organization. There, topics once as unanticipated as the remote nature of the meeting shared top billing: COVID-19 and racism.

San Diego 121
article thumbnail

Flagship Adds $1.1B for New Meds, More AI, & “Health Security”

Xconomy

Flagship Pioneering founder and CEO Noubar Afeyan didn’t know a global pandemic was in the cards for 2020 when he and his team laid out three new thematic areas of focus for the company last fall.

article thumbnail

Bio Roundup: So Long Celgene, RNAi’s Arrival, Pharma in 2020 & More

Xconomy

Bristol-Myers Squibb this week completed its acquisition of Celgene, a $74 billion deal that creates a pharmaceutical juggernaut. And all it took was the largest asset sale ever required by federal antitrust regulators.

article thumbnail

Biopharma Execs Remain Optimistic Despite Political Headwinds

Xconomy

Nevertheless, senior figures remain optimistic about the industry’s prospects in 2020. Nearly half of respondents believe that political and policy uncertainty present the greatest risks in 2020, with the latest Brexit developments and approaching UK and US elections seeing concerns around political volatility growing.

Pricing 78